Congenital Hemophilia with Inhibitors

Author: Danyal Ladha, University of Ottawa

Reviewer: Roy Khalife, University of Ottawa

Objectives

At the end of the self-assessment module, participants will be able to:

1. Understand the mechanism of action of Emicizumab prophylaxis in adult Hemophilia A patients with inhibitors.
2. Understand the indications for Emicizumab prophylaxis and benefits of its use in adult Hemophilia A patients with inhibitors.
3. Develop an approach to bleeding in a patient on Emicizumab prophylaxis.

CHS Scientific Planning Committee Members (2021-22)

Dr. Joanne Britto – Resident Physician, Hematology-Oncology
Dr. Yan Xu – Fellow Physician, Hematology
Dr. Siraj Mithoowani – Clinical Hematologist at St. Joseph’s Healthcare, Hamilton
Dr. Hassan Sibai – Assistant Professor of Medicine, Faculty of Medicine, University of Toronto and Staff Physician, Division of Medical Hematology & Oncology, Princess Margaret Cancer Centre

Conflicts of Interest: None